- Home
- DSM vs JSPR Comparison
DSM vs JSPR Comparison
Compare DSM & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.89
Company Overview
Basic Information| Metric | DSM | JSPR |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 48.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DSM | JSPR |
|---|---|---|
| Price | $5.98 | $1.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.44 |
| AVG Volume (30 Days) | 161.7K | ★ 3.9M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.69 | $1.39 |
| 52 Week High | $6.05 | $22.99 |
Technical Indicators
Market Signals| Indicator | DSM | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 51.88 |
| Support Level | $5.93 | $1.61 |
| Resistance Level | $6.09 | $1.93 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 54.00 | 45.15 |
Price Performance
Historical Comparison DSM
JSPR
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.